…
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Cencora Inc. is a global pharmaceutical distribution and services company that supplies medicines and provides specialty pharmacy, patient-support and manufacturer services to healthcare providers and biopharma firms. Long-term growth may be driven by rising demand for specialty and oncology therapies, greater outsourcing by drugmakers, and the company’s scale in complex logistics and cold-chain handling.
Key risks include regulatory and legal exposure, pricing and reimbursement pressure from payers and PBMs, competition from other large distributors, and execution or integration setbacks that could compress margins.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Income before tax | 2258.34M | 2003.97M | 2160.84M | 2183.06M | 2221.86M |
| Minority interest | -13.64M | -10.15M | 12.72M | 32.28M | -4.68M |
| Net income | 1554.17M | 1509.12M | 1745.29M | 1698.82M | 1539.93M |
| Selling general administrative | 6493.84M | 5661.11M | 5309.98M | 4848.96M | 3594.25M |
| Gross profit | 10141.52M | 8701.24M | 8959.49M | 8334.57M | 6774.43M |
| Reconciled depreciation | 1068.42M | 1118.84M | 963.90M | 693.89M | 514.79M |
| Ebit | 2678.09M | 2252.66M | 2734.64M | 2780.86M | 2894.01M |
| Ebitda | 3736.33M | 3364.33M | 3698.55M | 3474.76M | 3408.80M |
| Depreciation and amortization | 1058.24M | 1111.67M | 963.90M | 693.89M | 514.79M |
| Operating income | 3647.68M | 3040.13M | 2340.73M | 2366.38M | 2354.20M |
| Other operating expenses | 317685.14M | 290918.47M | 259487.81M | 235833.50M | 211145.04M |
| Interest expense | 419.75M | 248.68M | 228.93M | 210.67M | 182.54M |
| Tax provision | 690.52M | 484.70M | 428.26M | 516.52M | 677.25M |
| Interest income | 128.21M | 91.69M | 228.93M | 21.31M | 8.47M |
| Net interest income | -291.55M | -156.99M | -228.93M | -210.67M | -174.07M |
| Income tax expense | 690.52M | 484.70M | 428.26M | 516.52M | 677.25M |
| Total revenue | 321332.82M | 293958.60M | 262173.41M | 238587.01M | 213988.84M |
| Total operating expenses | 6493.84M | 5661.11M | 6273.89M | 5542.86M | 4099.42M |
| Cost of revenue | 311191.30M | 285257.36M | 253213.92M | 230252.44M | 207214.41M |
| Total other income expense net | -1389.34M | -1036.16M | -295.84M | -359.78M | -447.87M |
| Net income from continuing ops | 1567.81M | 1519.27M | 1732.58M | 1666.54M | 1544.61M |
| Net income applicable to common shares | 1554.17M | 1509.12M | 1745.29M | 1698.82M | 1539.93M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Total assets | 76590.11M | 67101.67M | 62558.75M | 56560.62M | 57337.81M |
| Intangible assets | 3774.18M | 4001.05M | 14005.90M | 4332.74M | 5256.93M |
| Other current assets | 2126.74M | 1714.52M | 1840.93M | 2192.50M | 2125.16M |
| Total liab | 74843.03M | 66314.93M | 61892.46M | 56489.34M | 56753.39M |
| Total stockholder equity | 1508.02M | 645.94M | 666.29M | -289.78M | 223.35M |
| Other current liab | 2391.59M | 2262.00M | 2353.82M | 2214.59M | 192.07M |
| Common stock | 2.97M | 2.96M | 666.29M | 2.93M | 2.91M |
| Capital stock | 2.97M | 2.96M | - | 2.93M | 2.91M |
| Retained earnings | 6534.23M | 5417.14M | - | 2977.65M | 1670.51M |
| Other liab | - | - | - | 7514.74M | 8064.89M |
| Good will | 13676.52M | 9318.03M | - | 8503.89M | 9030.53M |
| Other assets | 2812.78M | 2741.75M | 3618.85M | 1054.26M | 1017.60M |
| Cash | 4394.55M | 3231.24M | 2592.05M | 3388.19M | 2547.14M |
| Cash and equivalents | 4356.14M | 3132.65M | 2592.05M | 3388.19M | 2547.14M |
| Total current liabilities | 57820.54M | 54277.05M | 48831.20M | 43477.96M | 41358.64M |
| Current deferred revenue | - | - | -641.34M | - | 2856.41M |
| Net debt | 6353.26M | 3421.55M | 2195.41M | 2314.64M | 4136.78M |
| Short term debt | 371.56M | 781.10M | 641.34M | 1070.47M | 300.21M |
| Short long term debt | 117.78M | 576.33M | 641.34M | 1070.47M | 300.21M |
| Short long term debt total | 10747.81M | 6652.80M | 4787.46M | 5702.83M | 6683.92M |
| Other stockholder equity | -4127.80M | -3785.05M | 666.29M | -1439.39M | -1004.62M |
| Property plant equipment | 4087.55M | 3323.03M | 2135.17M | 3079.98M | 3230.14M |
| Total current assets | 52239.07M | 47717.81M | 42798.83M | 39589.76M | 38802.61M |
| Net tangible assets | - | - | - | -13048.18M | -14064.10M |
| Short term investments | - | - | - | 0.00M | 372.91M |
| Net receivables | 25225.30M | 23871.81M | 20911.08M | 18452.67M | 18389.05M |
| Long term debt | 7542.99M | 3811.74M | 4146.11M | 4632.36M | 6383.71M |
| Inventory | 20492.48M | 18998.83M | 17454.77M | 15556.39M | 15368.35M |
| Accounts payable | 54719.76M | 50942.16M | 45836.04M | 40192.89M | 38009.95M |
| Accumulated other comprehensive income | -901.38M | -989.12M | - | -1830.97M | -445.44M |
| Non currrent assets other | 2603.97M | 2428.76M | 3418.18M | 1761.66M | 1793.99M |
| Non current assets total | 24351.04M | 19383.85M | 19759.92M | 16970.86M | 18535.20M |
| Long term debt total | 7542.99M | 3811.74M | 4146.11M | 4632.36M | 6383.71M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Investments | -4977.29M | -618.10M | -2602.47M | -368.44M | -6141.58M |
| Change to liabilities | - | - | - | 3320.72M | 2049.17M |
| Total cashflows from investing activities | -4977.29M | -618.10M | -2602.47M | -368.44M | -6141.58M |
| Net borrowings | 3195.67M | -385.45M | - | -923.10M | 2216.55M |
| Total cash from financing activities | 2249.11M | -2330.99M | -2222.28M | -1752.78M | 1952.85M |
| Change to operating activities | - | - | - | -854.72M | 276.14M |
| Net income | 1567.81M | 1519.27M | 1732.58M | 1666.54M | 1544.61M |
| Change in cash | 1096.67M | 544.99M | -840.65M | 523.41M | -1527.62M |
| Begin period cash flow | 3297.88M | 2752.89M | 3593.54M | 3070.13M | 4597.75M |
| End period cash flow | 4394.55M | 3297.88M | 2752.89M | 3593.54M | 3070.13M |
| Total cash from operating activities | 3875.12M | 3484.68M | 3911.33M | 2703.09M | 2666.59M |
| Issuance of capital stock | - | - | - | 0.00M | 0.00M |
| Depreciation | 1051.08M | 448.20M | 963.90M | 709.84M | 514.79M |
| Other cashflows from investing activities | -4309.31M | -130.92M | -2144.11M | 127.88M | -5703.36M |
| Dividends paid | 437.08M | 416.17M | -398.75M | -391.69M | -366.65M |
| Change to inventory | -1269.43M | -1479.60M | -2183.37M | -665.37M | -1116.34M |
| Change to account receivables | -1923.41M | -2784.34M | -2711.79M | -1659.53M | -930.08M |
| Sale purchase of stock | -435.47M | -1491.37M | -1180.73M | -483.70M | -82.15M |
| Other cashflows from financing activities | -103.14M | -75.85M | -19.54M | -48.20M | -13.65M |
| Change to netincome | - | - | - | 434.10M | 244.55M |
| Capital expenditures | 667.98M | 487.17M | 458.36M | 496.32M | 438.22M |
| Change in working capital | 35.42M | 298.69M | 874.54M | -139.66M | 367.32M |
| Stock based compensation | 147.96M | 148.00M | - | 93.40M | 99.59M |
| Other non cash items | 2271.88M | 1172.85M | 340.31M | 176.79M | -194.59M |
| Free cash flow | 3207.14M | 2997.51M | 3452.97M | 2206.77M | 2228.37M |
Sector: Healthcare Industry: Medical Distribution
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| COR Cencora Inc. |
13.60 3.99% |
354.10 | 24.22 | 16.39 | 0.19 | 20.41 | 0.21 | 13.72 |
| MCK McKesson Corporation |
69.82 6.98% |
1069.44 | 24.45 | 20.41 | 0.26 | 5.04 | 0.27 | 15.03 |
| CAH Cardinal Health Inc |
8.99 3.55% |
261.93 | 29.48 | 17.92 | 0.20 | 16.07 | 0.22 | 15.67 |
| HSIC Henry Schein Inc |
- -% |
88.24 | 25.89 | 15.08 | 0.72 | 3.14 | 1.00 | 13.43 |
| SHTDY SINOPHARM GROUP CO LTD ADR |
0.11 1.04% |
10.69 | 6.18 | 7.49 | 0.01 | 0.76 | 0.03 | 0.72 |
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
1 West First Avenue, Conshohocken, PA, United States, 19428-1800
610 727 7000
47000
| Name | Title | Year Born |
|---|---|---|
| Mr. Steven H. Collis | Chairman, Pres & CEO | 1961 |
| Mr. James F. Cleary Jr. | Exec. VP & CFO | 1963 |
| Dr. Robert P. Mauch Ph.D., PharmD | Exec. VP & COO | 1967 |
| Ms. Gina K. Clark | Exec. VP and Chief Communications & Admin. Officer | 1957 |
| Mr. John G. Chou | Exec. VP and Special Advisor to the Chairman & CEO | 1956 |
| Mr. Lazarus Krikorian | Sr. VP, Chief Accounting Officer & Corp. Controller | 1965 |
| Bennett S. Murphy | Sr. VP of Investor Relations | NA |
| Ms. Kathy H. Gaddes | Exec. VP & Chief Compliance Officer | 1963 |
| Ms. Elizabeth S. Campbell | Exec. VP & Chief Legal Officer | 1975 |
| Ms. Silvana Battaglia | Exec. VP & Chief HR Officer | 1967 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.